Search results
Showing 1 to 15 of 8099 results
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Tell us about an interventional procedure you think should be assessed by NICE.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD....
View recommendations for HTE18Show all sections
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
Embed NICE content in your digital products and services with our syndication API
Technology appraisals are recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.
Our methods and processes (health technology evaluation manual)
Our health technology evaluation manual covers: how we choose medicines and other health technologies to evaluate (topic selection) the steps and...
Costs: charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
The technology appraisal committee can make 5 types of recommendation: Recommended, Optimised, Recommended for use in the Cancer Drugs Fund, Only in research, and Not recommended.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS. Browse technology...
We're excited that you're interested in joining a committee and helping us improve health and social care services. By joining, you'll have the...
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
NICE executive team meeting minutes and agenda